Literature DB >> 35104739

Mediational pathways of tobacco use among adult daily smokers with psychiatric symptoms in the Population Assessment of Tobacco and Health (PATH) survey.

Teresa DeAtley1, Alexander W Sokolovsky2, Morgan L Snell2, Jennifer Tidey2.   

Abstract

INTRODUCTION: Individuals with psychiatric conditions suffer disproportionately from tobacco-related morbidity and mortality, but the factors driving this relationship remain unclear. We used data from the Population Assessment of Tobacco and Health (PATH) to investigate whether associations between internalizing psychiatric symptoms and change in smoking heaviness (as measured by cigarettes per day (CPD) were mediated by self-reported respiratory symptoms, smoking risk perceptions, and cigarette dependence.
METHODS: This study used data from PATH Waves 1 through 4 (2013-2017, n = 4,152). Psychiatric symptoms were indexed with the internalizing sub-scale of the Global Appraisal of Individual Needs-Short Screener (GAIN-SS) among daily smokers. We fit auto-regressive structural equation models (SEM) to data from Wave 1-3 and 2-4 to determine the direct and indirect associations between internalizing symptom scores and CPD through each mediator.
RESULTS: The association between internalizing symptoms and CPD was mediated by cigarette dependence (indirect: B = 0.004, SE = 0.041, p = 0.023) and respiratory symptom severity (indirect: B = 0.018, SE = 0.097, p < 0.001). Internalizing symptoms predicted higher harm perceptions (B = 0.056, SE = 0.035, p < 0.001) but the indirect relationship with CPD was non-significant. Findings from Waves 2-4 replicated these results.
CONCLUSION: Our results indicate that cigarette dependence and respiratory symptom severity partially mediate the relationship between internalizing symptoms and CPD but risk perceptions were not significant predictors in our models. This suggests that efforts to reduce smoking among people with internalizing disorders should focus on decreasing nicotine dependence and increasing awareness of respiratory symptoms to encourage a quit attempt or switch to a less harmful source of nicotine.
Copyright © 2022 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Longitudinal mediation; Psychiatric symptoms; Smoking heaviness

Mesh:

Year:  2022        PMID: 35104739      PMCID: PMC8969557          DOI: 10.1016/j.addbeh.2022.107249

Source DB:  PubMed          Journal:  Addict Behav        ISSN: 0306-4603            Impact factor:   3.913


  34 in total

Review 1.  Anxiety, depression, and cigarette smoking: a transdiagnostic vulnerability framework to understanding emotion-smoking comorbidity.

Authors:  Adam M Leventhal; Michael J Zvolensky
Journal:  Psychol Bull       Date:  2014-11-03       Impact factor: 17.737

2.  A Protection Motivation Theory of Fear Appeals and Attitude Change1.

Authors:  Ronald W Rogers
Journal:  J Psychol       Date:  1975-09

3.  Population-level patterns and mental health and substance use correlates of alcohol, marijuana, and tobacco use and co-use in US young adults and adults: Results from the population assessment for tobacco and health.

Authors:  Amy M Cohn; Amanda L Johnson; Shyanika W Rose; Jennifer L Pearson; Andrea C Villanti; Cassandra Stanton
Journal:  Am J Addict       Date:  2018-09

4.  Depression, anxiety, and COPD: the unexamined role of nicotine dependence.

Authors:  Renee D Goodwin; Kim L Lavoie; Adina R Lemeshow; Elizabeth Jenkins; E Sherwood Brown; David A Fedoronko
Journal:  Nicotine Tob Res       Date:  2011-10-24       Impact factor: 4.244

5.  Cancer-Related Risk Perceptions and Beliefs in Texas: Findings from a 2018 Population-Level Survey.

Authors:  Sonia A Cunningham; Robert Yu; Tina Shih; Sharon Giordano; Lorna H McNeill; Ruth Rechis; Susan K Peterson; Paul Cinciripini; Lewis Foxhall; Ernest Hawk; Sanjay Shete
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-01-30       Impact factor: 4.254

6.  Design and methods of the Population Assessment of Tobacco and Health (PATH) Study.

Authors:  Andrew Hyland; Bridget K Ambrose; Kevin P Conway; Nicolette Borek; Elizabeth Lambert; Charles Carusi; Kristie Taylor; Scott Crosse; Geoffrey T Fong; K Michael Cummings; David Abrams; John P Pierce; James Sargent; Karen Messer; Maansi Bansal-Travers; Ray Niaura; Donna Vallone; David Hammond; Nahla Hilmi; Jonathan Kwan; Andrea Piesse; Graham Kalton; Sharon Lohr; Nick Pharris-Ciurej; Victoria Castleman; Victoria R Green; Greta Tessman; Annette Kaufman; Charles Lawrence; Dana M van Bemmel; Heather L Kimmel; Ben Blount; Ling Yang; Barbara O'Brien; Cindy Tworek; Derek Alberding; Lynn C Hull; Yu-Ching Cheng; David Maklan; Cathy L Backinger; Wilson M Compton
Journal:  Tob Control       Date:  2016-08-08       Impact factor: 7.552

7.  Respiratory and Bronchitic Symptoms Predict Intention to Quit Smoking among Current Smokers with, and at Risk for, Chronic Obstructive Pulmonary Disease.

Authors:  Anne C Melzer; Laura C Feemster; Kristina Crothers; Shannon S Carson; Suzanne E Gillespie; Ashley G Henderson; Jerry A Krishnan; Peter K Lindenauer; Mary Ann McBurnie; Richard A Mularski; Edward T Naureckas; A Simon Pickard; David H Au
Journal:  Ann Am Thorac Soc       Date:  2016-09

8.  Depressive symptoms and smokers' perceptions of lung cancer risk: moderating effects of tobacco dependence.

Authors:  Anna H L Floyd; J Lee Westmaas; Valerie Targhetta; Anne Moyer
Journal:  Addict Behav       Date:  2008-10-11       Impact factor: 3.913

Review 9.  Assessing motivation to quit smoking in people with mental illness: a review.

Authors:  Ranita Siru; Gary K Hulse; Robert J Tait
Journal:  Addiction       Date:  2009-05       Impact factor: 6.526

10.  Effects of 6-Week Use of Very Low Nicotine Content Cigarettes in Smokers With Serious Mental Illness.

Authors:  Jennifer W Tidey; Suzanne M Colby; Rachel L Denlinger-Apte; Christine Goodwin; Patricia A Cioe; Rachel N Cassidy; Robert M Swift; Bruce R Lindgren; Nathan Rubin; Sharon E Murphy; Stephen S Hecht; Dorothy K Hatsukami; Eric C Donny
Journal:  Nicotine Tob Res       Date:  2019-12-23       Impact factor: 4.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.